CNM-Au8 produced statistically significant declines in neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) with signals that track to survival in ALS. In the NIH-sponsored expanded access program, the Week 36 NfL AUC geometric mean ratio was 0.914 versus matched controls (95% CI 0.840–0.995; p=0.0373), mirroring the effect in the HEALEY ALS Platform Trial double-blind phase at Week 24 (GMR 0.901; 95% CI 0.845–0.959; p=0.0013). GFAP declined significantly and correlated closely with NfL (Pearson’s r >0.85; p<0.0001). Open-label switchers from placebo showed NfL stabilization or decline by Week 28 (GMR 0.885; 95% CI 0.737–1.063; p=0.185) and a restricted mean survival time gain of 30.7 days at one year (95% CI 7.52–53.85; p=0.0094). In HEALEY/OLE survival analyses, CNM-Au8 30 mg was associated with a 73% lower risk of death at one year in the full analysis set (HR 0.272; 95% CI 0.096–0.772; p=0.014) and 77% in a risk-balanced set (HR 0.229; 95% CI 0.07–0.752; p=0.015). Participants with the largest NfL and GFAP declines had an 80% lower risk of death versus concurrent controls (HR 0.191; 95% CI 0.047–0.782; p=0.021). Across more than 1,000 patient-years of exposure, no treatment-related serious adverse events were identified. The company has completed FDA-recommended analyses to bolster the persuasiveness of the biomarker findings and has requested a Type C meeting in the first quarter of 2026 to support an accelerated approval filing for CNM-Au8 in ALS. The package integrates HEALEY double-blind and open-label data, new GFAP analyses, and outcomes from the NIH expanded access program benchmarked against matched external controls from the ANSWER ALS dataset. The planned NDA would be paired with RESTORE-ALS as the post-approval confirmatory study. Strategically, this is an explicit bid to anchor an ALS submission in convergent biomarker signals linked to survival, aligning with FDA’s growing receptivity to NfL as a disease-relevant measure while adding GFAP to strengthen biological plausibility. The pivot to an NIH-backed EAP with external controls reflects a practical response to the scarcity and heterogeneity of ALS trial populations and the operational advantages of real-world accrual. It also introduces regulatory tension: acceptance of external comparators, modeling choices for survival against concurrent regimen controls, and modest sample sizes in open-label subsets will be scrutinized. Notably, the primary non-bulbar subgroup in the NIH-EAP missed significance on the Week 36 NfL AUC, an inconsistency FDA will likely interrogate. For sponsors and CROs, the signal is clear that biomarker-forward ALS programs are viable if assays, datasets, and statistical frameworks are audit-ready. Sites should expect tighter biospecimen logistics, central lab dependencies, and harmonized NfL/GFAP platforms, as well as closer integration with registries for external control matching. Regulators will focus on assay standardization, handling of real-world confounding, and the robustness of covariate-adjusted survival models. Clinically, the absence of functional endpoint gains in the current disclosure keeps payer and uptake questions contingent on confirmatory performance. Near term, watch the Type C readout: sufficiency of dual biomarkers, the credibility of the ANSWER ALS matching strategy, and whether an advisory committee is requested. The design readiness and powering of RESTORE-ALS—endpoint selection, survival vs. composite, and global site capacity—will determine durability of any accelerated path. Manufacturing scale-up and assay harmonization across regions could become gating factors. More broadly, this filing will test how far FDA will extend accelerated approval in neurodegeneration on coherent but nontraditional evidence stacks that blend platform trials, EAP data, and external controls.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
